Возможности коррекции массы тела: польза и риски

1. Williams Textbook of Edocrinology, edition 11 2009.
2. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care 2001; 24 (4): 683–9.
3. Задионченко B.C., Адашева Т.В., Демичева О.Ю. и др. Метаболический синдром и ожирение: Артериальная гипертония при метаболическом синдроме: патогенез, основы терапии. Cons. Med. 2004; 9: 45–52.
4. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности первичной профилактики цереброваскулярных осложнений у больных с метаболическим синдромом и артериальной гипертонией. Кардиол. вестн. 2006; I (XII): 29–32.
5. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children : quick reference guide 1: for local authorities, schools and early years providers, workplaces and the public. London: National Institute for Health and Clinical Excellence; 2006.
6. Snow V, Barry P, Fitterman N et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142 (7): 525–31.
7. Ayyard and Anderson. Ob Rev 2000; 1: 113–9.
8. Laaksonen DE, Lindstrom J, Lakka TA et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005; 54: 158–65.
9. Овчинников А.Г. Ожирение и сердечно-сосудистая система. Сердце. 2005; 4 (5): 243–53.
10. Грунди М.С. Медикаментозная терапия метаболического синдрома: минимизация развивающегося процесса полипрагмазии. Обзоры клинич. кардиол. 2007; 11: 2–25.
11. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care 2008; 31 (Suppl. 2): 269–77.
12. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71–7.
13. Grundy SM., Hansen B, Smith SC et al. Clinical Management of Metabolic Syndrome Circulation. 2004; 109: 551–6.
14. Atkinson RL, Blank RC, Loper JF et al. Combined drug treatment of obesity. Obes Res 1995; 3 (Suppl. 4): 497–500.
15. Questions and answers on the suspension of medicines containing sibutramine Outcome of a procedure under Article 107 of Directive 2001/83/EC6 August 2010 EMA/808179/2009 rev EMEA/H/A-107/1256 http://www.ema.europa.eu/docs/en_GB/ document_library/Referrals_document/Sibutramine_107/WC500094238.pdf.
16. Sibutramine (Meridia) withdrawn. Med Lett Drugs Ther 2010; 52 (1350): 88.
17. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010; 340: 824.
18. Zhi J, Melia AT, Eggers H et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in health human volunteers. J Clin Pharmacol 1995; 35: 1103–8.
19. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155–61.
20. Мельниченко Г.А., Комшилова К.А., Берковская М.А. Опыт применения препарата Орсотен (орлистат) у больных ожирением. Ожирение и метаболизм. 2010; 1: 31–5.
21. Rossner S, Sjostrom L, Noack R et al. Obesity Research 2000; 1: 49–61.
22. Hauptman J, Lucas C, Boldrin M et al. Arch Fam Med 2000; 9: 160–7.
23. Anderson J, Schwartz S, Hauptman J et al. Ann Pharmacother 2006; 40: 1717–23.
24. Max H. Pittler and Edzard Ernst Dietary supplements for body-weight reduction: a systematic Review. Am J Clin Nutr 2004; 79: 529–36.
25. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. Med J Aust 1999; 171: 604–8.
26. Onakpoya IJ, Wider B, Pittler MH, Ernst E. Food supplements for body weight reduction: a systematic review of systematic reviews. Obesity (Silver Spring) 2011; 19 (2): 239–44.
27. Dave S, Kaur NJ, Nanduri R et al. Inhibition of adipogenesis and induction of apoptosis and lipolysis by stem bromelain in 3T3-L1 adipocytes. PLoS One 2012; 7 (1): e30831. Epub 2012. Jan 24.
28.  Bempong DK, Houghton PJ, Steadman K.The Xanthine Content of Guarana and Its Preparations. Pharmaceutical Biol 1993.
29. Guoyi Ma et al. Pharmacological Effects of Ephedrine Alkaloids on Human {alpha}1- and {alpha}2-Adrenergic Receptor Subtypes. J Pharmacol Exp Ther; 322: 214–21.
30. Nortier JL, Muniz Martinez M-C, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochiafangchi). N Engl J Med 2000; 342: 1686–92.
31. Lewis CJ, Alpert S. Letter to Health Care Professionals on FDA Concerned about Botanical Products, Including Dietary Supplements, Containing Aristolochic Acids. US Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling and Dietary Supplements, 31 May 2000.
32. WHO Traditional Medicine Strategy 2002–2005. May 2002. Available at: http://www.who.int/medicines/organization/trm/ orgtrmmain.shtml. Accessed July 27, 2002.
33. Nortier JL, Muniz Martinez M-C, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochiafangchi). N Engl J Med 2000; 342: 1686–92.

О.В.Дралова 

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ